JP2010508309A - Composition for the treatment of skin diseases - Google Patents

Abstract

  A composition for the treatment of various skin diseases, wherein the composition comprises at least one column containing a packed solid consisting of a crushed mollusk shell and having a diameter of at least one. Contains the solution that has been passed through once This solution is then mixed with a pharmaceutically acceptable carrier. This composition also has an effective use as a cleansing agent and has been found to be beneficial in the treatment of skin diseases and other diseases of the body. Furthermore, the shell can be crushed and used as an active ingredient in the production of ointments useful in medicine.

Description

FIELD OF THE INVENTION This invention relates generally to topical compositions comprising an active solution mixed with a pharmaceutically acceptable carrier, which solution is repeated through a filter / extraction column containing crushed mollusk shell particles. Manufactured by filtering liquid. This composition can be used for the treatment of various skin diseases.

BACKGROUND OF THE INVENTION The present invention is an improvement over Canadian Patent Application No. 2,566,562, which discloses a method for preparing a solution for use in the treatment of skin diseases. Further results have been revealed outlining the use of the above solutions to produce new compositions. The reader is invited to refer to Canadian Patent Application No. 2,556,562 so that the solution itself and its method of manufacture can be easily understood.

  Mollusk-derived shells are generated as industrial waste from fishing grounds around the world. This shell waste is customarily dropped into the sea. However, shells have been effectively utilized as a calcium source and to obtain antibacterial agents, as well as for water purification. Powders obtained from scallops, oysters, clams and other mollusk shells, and solutions containing such powders have been shown to have antibacterial and antiviral properties and uses as water purification agents. It has also been found that the above powders have shown useful properties when applied as a deodorant for sterilization, as a preservative, and in selected pharmaceutical applications.

  The pharmacological action of mollusk shell powders and extracts has been well documented and tested. For example, European Patent Application No. 1676583 describes a therapeutic agent for periodontal disease that is prepared using scallop shell material and has antibacterial activity against bacteria that induce periodontal disease. In particular, the shell is subjected to firing after being pulverized in order to convert the calcium carbonate of the original shell into calcium oxide by firing at high temperature. Next, an aqueous solution is formed from the newly formed calcium oxide powder and the original calcium carbonate powder.

  US Patent Application 2004/0028748 describes a dermatophytosis treatment obtained from a product formed by grinding a shell having a crystalline structure and forming an aqueous dispersion of the product. . In particular, the ground shell is fired by heating the particles above 1000 ° C., and an aqueous solution is obtained using both the initially ground shell and the fired shell.

  Japanese Patent Application No. 2004/256785 describes a soap having an auxiliary therapeutic effect to relieve the itching associated with atopic dermatitis and psoriasis. The main active ingredient of this soap is a fine powder prepared by high-temperature baking such as scallop shell, oyster shell, clam shell.

  US Pat. No. 6,627,229 is manufactured by applying a heat treatment at 700-1200 ° C. to a ground powder of animal-derived calcium-containing materials such as bivalves, crustacean shells, bones, corals and pearls Antiviral drugs to be described are described.

US Pat. No. 6,365,193 and US Pat. No. 6,488,978 to Sasaki et al. Disclose that the burned shell can be used as an antibacterial and water purification agent. Sasaki et al. Disclose heating the shell under an inert gas atmosphere to burn the shell. In particular, the antibacterial agent is obtained by burning powder derived from a shell of a sea shell in an inert gas atmosphere. This powder can be easily dissolved in water and used as an antimicrobial solution.

  The use of shells as described above represents a wide range of applications where shell properties can be exploited. In order to manage and reduce the large volume of shell waste produced annually, further development directed to new uses of shell materials is desired and needed.

  Most of the above applications require the use of crushed or powdered shells obtained from mollusk shells, and in all cases, heat treatment at high temperatures is employed to fire the shell particles. Neither of these procedures can be expensive equipment or equipment to achieve such high temperatures when it may not actually require a firing step to reveal the intrinsic pharmacological action of the shell particles. Requires complicated setup procedures.

  In addition, the majority of therapeutics prescribed and / or recommended by physicians for skin disorders contain harsh chemicals such as lower monohydric alcohols, ie ethanol and isopropanol. However, the high content of these alcohols in therapeutic agents often causes dryness and irritation of the skin to which the therapeutic agent is applied. Because the present invention does not use these added and other additives, the side effects associated with these chemicals are minimized.

SUMMARY OF THE INVENTION An object of the present invention is to provide a composition that is composed of an extract derived from mollusk shells and contains mainly calcium, and is safe for the human body and friendly to the environment. In addition, the composition inherits the antibacterial, antiviral and ancillary healing properties of the shell and can be effectively utilized in the treatment of skin diseases, as has been shown so far. Furthermore, it is desirable that the composition does not cause significant dryness or irritation of the skin.

  Furthermore, the composition of the present invention and its method of preparation are simple and therefore economically advantageous. Accordingly, the composition of the present invention is available to the general public at an affordable price.

  According to one aspect of the present invention, a topical composition comprising an active solution mixed with a pharmaceutically acceptable carrier, wherein the solution is a filter / extraction containing crushed mollusk shell particles Compositions are provided that are produced by repeatedly filtering a liquid through a column.

  According to another aspect of the present invention, there is provided a topical composition comprising ground mollusc shell microparticles mixed with a pharmaceutically acceptable carrier.

  According to a further aspect of the present invention, there is provided a topical composition comprising dissolving ground mollusk shell particles in a solution.

  These and other features of the invention will become more apparent from the accompanying drawings.

It is sectional drawing of the extraction column containing an inlet, a discharge port, and a housing member. It is an exploded cross-sectional view of the upper half of the extraction column, depicting an empty column setting. FIG. 4 is an exploded cross-sectional view of the upper half of the extraction column, depicting a column filled with a packing member. It is an exploded sectional view of the lower half of the extraction column, depicting an empty column setting. FIG. 2 depicts a cross-sectional view of an apparatus that includes two extraction columns arranged in series. It is a figure which shows the measured turbidity of an active solution with exposure time. FIG. 5 shows the increase in the amount of calcium measured in the active solution with the exposure time. It is a figure which shows the change which generate | occur | produced in pH of the active solution with exposure time, and also compares the effect with respect to pH of the shell particle from which the ratio with respect to a solvent differs. It is a figure which shows the change which generate | occur | produced in the electrical conductivity of the active solution with exposure time, and also compares the effect with respect to the electrical conductivity of the shell particle from which the ratio with respect to a solvent differs. FIG. 5 shows the change in the amount of calcium recovered in the active solution with the exposure time, and also compares the effect of shell particles with different ratios to solvent on calcium.

  One component of one embodiment of the present invention is an active solution mixed with a pharmaceutically acceptable carrier. The method for producing the active solution is similar to that disclosed in Canadian Patent Application No. 2,556,562, which is the priority document of the present application, and will be described herein with reference to the drawings.

  FIG. 1 depicts a filter / extraction column (10) including an inlet (11), an outlet (13), two screens (14) and a housing member (12). The housing member (12) defines a passageway (12a) that can be filled with a crushed mollusk shell.

  FIG. 2a depicts an exploded view of the upper half of the filter / extraction column (10), which comprises an upper coupling (16), a screw-on stopper (15) and the stopper. It includes a discharge port (13) arranged at (15). A screen (14) may be placed on the housing member (12) to accommodate the crushed mollusk shell in the filter / extraction column (10). The upper coupling (16) is fitted with a coupling inner lip (17) so that the screen (14) can be attached to the housing member. To prevent leakage of the column, a replaceable seal (18) such as silicon can be used.

  FIG. 2b depicts an exploded view of the lower half of the extraction column, which comprises a lower coupling (16), a stopper (15) and an inlet (11) located in the stopper (15). including. The lower coupling is fitted with a coupling inner lip (17) so that a screen (14) can be attached to the housing member (12) to accommodate the crushed mollusk shell in the filter / extraction column. can do. The inlet (11) is designed to connect to a plastic valve or a pump used to supply solvent to the column. In order to avoid leakage of the column, a replaceable silicon seal (18) can be used.

FIG. 3 depicts a filter / extraction column (10) that includes an inlet (11), an outlet (13), the top and bottom identical screens (14), and a housing member (12). The housing member (12) contains crushed mollusk shell particles, the size of which may be the same or different. In one embodiment shown in FIG. 3, the housing member contains ground shell particles (20) having a diameter of 0.5-1 mm at the bottom and a ground shell of 3-4 mm in diameter at the top. Contains particles (21). However, the crushed mollusk shells may have roughly equal sized particles evenly distributed along the passageway in one or more areas as needed for filter / extraction. An area is defined as containing ground shell particles of approximately the same diameter. The packing of the ground shell particles into the column can follow a regular or irregular distribution according to the desired gradient.

  FIG. 4 depicts a cross-sectional view of the device (1) according to the invention, comprising at least two filter / extraction columns (2, 3) arranged in series. In this two-column apparatus (1), the filter / extraction column is such that the outlet (13) of the first column (2) is connected to the inlet (11) of the second column (3) by a connection tube (23). So that they are arranged linearly. The casing member (12) of the first column (2) can accommodate crushed shell particles (20) having a diameter of 0.5 to 1 mm at the bottom thereof, and then crushed shell particles having a diameter of 3 to 4 mm. (21) can be accommodated. The housing member (12) of the second column (3) may contain crushed shell particles (24) coated with iron oxide or hematite. Coating the milled shell particles with iron oxide or hematite can substantially improve the purification characteristics of the filter / extraction column by reducing the metal content in the solution passing through the device (1). It is considered. Analysis of the water that passed through the filter / extraction column apparatus (1) showed that the content of aluminum and arsenic in the active solution was almost zero.

  In practicing the method of the invention for producing an active solution, the shells are recovered as soon as they get off the fishing boat and placed in a transport box for transport to the manufacturing plant. The shell is then cleaned with an electric drill and wire brush and thoroughly washed under high pressure to ensure effective cleaning. Subsequent to the cleaning and washing steps, a cooling step may be provided in which the shell is allowed to rest on the metal screen for the length of time necessary to cool the shell to ambient temperature. In the next step, the shell is then subjected to a heat treatment such that the shell reaches a temperature of about 100 ° C. to about 300 ° C. by any means known to those skilled in the art, such as boiling or calcination. The main purpose of heat treatment is to remove any remaining mollusc tissue, forcibly open the pores inherent in the shell, and remove the protective layer to further expose the inner layer of the shell That is. This heat treatment facilitates leaching of the inner layer containing most of the active ingredient when used in the above equipment.

  At this point, the entire shell is ground by any means known to those skilled in the art. Next, the obtained particles are classified and sorted by size using a sieve, a filter, or the like. Preferably, scallop shell particles with a diameter of about 1-6 mm are selected, more preferably with a diameter of about 2-5 mm, and most preferably with a diameter of about 3-4 mm. Although particles in the size range of about 10 μm to about 25 mm can be used, these particles are still included within the scope of the present invention. These particles are then introduced into the filter / extraction column. Also, particles of approximately the same diameter or a mixture of particles having different diameters can be used in the filter / extraction column according to the present invention.

  The effectiveness of the active solution, and thus the effectiveness of the composition itself, depends on several factors such as the pH of the solvent used and the particle size of the ground shell that forms the packing member of the extraction column. Preferably the solvent is water. More preferably, the solvent is distilled water or reverse osmosis purified water. By passing water through the filter / extraction column (10), in particular the turbidity, pH, calcium content, conductivity and suspended solids of the active solution can be controlled. The number of passes, the flow rate of water and the ratio of water to shell in the column determine the properties of the active solution and thus the properties of the composition itself. It has been shown that the size of the ground shell is relatively inversely proportional to the effectiveness of the composition. For example, in order to produce an active solution effective as a topical composition when combined with an acceptable carrier, the particle size of the ground shell is preferably 1-6 mm, more preferably 2-5 mm. And most preferably 3-4 mm.

FIG. 5 shows the turbidity versus exposure time measured in Example 1 detailed below. It will be seen that the measured turbidity of the active solution decreases with the exposure time of the filter / extraction column. Turbidity was measured after each solvent passed through the extraction column. After a 12 hour exposure time, the measured solution had a measured turbidity of about 2.2 NTU. Each measured value of said turbidity correlates with the measured value of the amount of suspended solids in the active solution after each passage. Thus, as shown in Table 1 of Example 1, after the solvent first passed through the filter / extraction column, the amount of suspended solids decreased from 6 mg / L over time and reached about 0 mg / L after 12 hours. Become.

  FIG. 6 shows the amount of calcium versus exposure time measured after each time the water passed through the extraction column. The final active solution contains about 121 times more calcium than the starting solvent. The calcium content of the active solution is preferably more than 14 mg / L, more preferably more than 20 mg / L. Other factors that can affect the effectiveness of the active solution and thus the composition are the pH and turbidity of the active solution. In order to be able to withstand topical application while optimizing the effectiveness of the active solution, the pH of the active solution is preferably 6.0 to 10.0, more preferably 6.5 to 9.0, most preferably Is 7.0 to 8.0. Turbidity must be less than 6 NTU units.

  According to one embodiment of the present invention, an active solution (wherein the active solution is produced by repeatedly filtering the liquid through a filter / extraction column containing crushed mollusk shell particles) When it has been mixed with a pharmaceutically acceptable carrier after obtaining all its desired properties. The specific method or process used to combine the active solution with the pharmaceutically acceptable carrier is not limited, and any type of mixing method utilizing any type of known mixing device within the scope of the present invention. Can be considered.

  A preferred process for mixing the active solution with an acceptable carrier involves utilizing a common kitchen mixing device. All of the active solution is added at the beginning of the process in half-full increments to half the total weight of the acceptable carrier. After thorough mixing has taken place, the remaining carrier is added to the composition and incorporated. The advantage of this process is that the generation of bubbles in the composition is greatly reduced and it is easier to ensure a certain consistency of the product.

  The pharmaceutically acceptable carriers of the present invention can be, but are not limited to, creams, lotions, gels, ointments and pastes. Preferably, the carrier is petrolatum, base emulsifying ointment, or euthelin. More preferably, the carrier is a base emulsifying ointment or Euserin®. In other embodiments of the invention, the carrier may comprise any combination of the above compounds.

  According to one embodiment of the present invention, when the acceptable carrier is Euselin®, the active solution is mixed with Euselin® in a ratio of about 1: 1 to about 7: 1 by weight. The Preferably, the ratio of active solution to Euselin® is 7: 1 by weight. The upper limit of these proportions depends on the ability of the active solution to be incorporated into Euselin®. At the upper limit of the specified ratio, ie 7: 1, Euserin® saturates and no further incorporation is possible when an active solution is subsequently added. Thus, any ratio of active solution to Euserin® that allows for supersaturation of Euselin® with the active solution is included within the scope of the present invention. These proportions result in a cream that can be easily applied to the skin.

According to one embodiment of the present invention, when the acceptable carrier is a base emulsifying ointment, the active solution is mixed with the base emulsifying ointment in a ratio of about 0.5: 1 to about 7: 1 by weight. The Preferably, the ratio of active solution to base emulsified ointment is 5: 1 by weight. The upper limit of these proportions depends on the ability of the active solution to be incorporated into the base emulsifying ointment. The base emulsified ointment saturates at the upper limit specified, i.e. 7: 1, and no further incorporation is possible after the addition of the active solution. Accordingly, any ratio of active solution to base emulsifying ointment that allows supersaturation of the base emulsifying ointment with the active solution is included within the scope of the present invention. These proportions result in a cream that is smooth and easily applied to the skin and appears to be easily absorbed through the pores of the skin.

  According to another embodiment of the present invention, a composition is formed when crushed mollusk shell microparticles are added to a pharmaceutically acceptable carrier. In the present invention, “crushed mollusk shell fine particles” are defined as crushed mollusk shell particles having a diameter of 250 μm or less. More preferably, the crushed mollusk shell particles have a diameter of 150 μm or less. The pharmaceutically acceptable carrier is as defined above.

  The crushed mollusk shell particles are prepared according to the crushed mollusk shell particles of the present invention. That is, after sufficiently cleaning the shell, the shell is subjected to a heat treatment such that the shell reaches a temperature in the range of about 100 ° C. to about 300 ° C. by any means known to those skilled in the art, such as boiling or baking. The shell is then ground by any means known to those skilled in the art. The resulting particles are then sorted and sorted by size using a sieve, filter or the like. It is during this sorting process that the crushed mollusk shell particles are observed. These crushed mollusk shell particles are then incorporated into a composition containing a pharmaceutically acceptable carrier. Preferably, the microparticles are incorporated into the composition at about 0.01% to 0.5% by weight. More preferably, the microparticles are incorporated into the composition at about 0.03% by weight. A limitation on the addition of microparticles to the composition is that the particles are fine but still inherently very coarse. Thus, it has been found that the use of the composition is limited when the microparticles are incorporated into the composition at a weight percent higher than the above range. This is because the composition tends to be excessively grainy and destructive and when applied to the skin severely dries the skin.

  According to a preferred embodiment of the present invention, a composition is formed when the active solution of the present invention is mixed with a pharmaceutically acceptable carrier, wherein the crushed mollusk shell microparticles are subsequently Added to the product. Similar to the above parameters, when the carrier is Euselin®, the ratio of active solution to carrier is about 1: 1 to about 7: 1 by weight. Preferably, the ratio of active solution to Eucerin® is 7: 1 by weight. When the carrier is a base emulsified ointment, the ratio of active solution to carrier is about 0.5: 1 to about 7: 1 by weight. Preferably, the ratio of active solution to base emulsified ointment is 5: 1 by weight. The fine particles are the same as described above. Preferably, the microparticles are incorporated into the composition of this embodiment at about 0.01% to 0.5% by weight. More preferably, the microparticles are incorporated into the composition at about 0.03% by weight. A limitation on the addition of microparticles to the composition is that the particles are fine but still inherently very coarse. Thus, it has been found that the use of the composition is limited when the microparticles are incorporated into the composition at a weight percent higher than the above range. This is because the composition tends to be excessively grainy and destructive and when applied to the skin severely dries the skin.

  A further embodiment of the present invention is the use of any of the above compositions for topical application. Preferably, the use of any of the compositions according to the invention is for treating at least one skin disease. More preferably, the use of the composition according to the invention is for treating at least one skin disease, wherein the at least one skin disease is a skin disease associated with psoriasis, acne, shingles, varicella-zoster virus. Selected from the group consisting of insect bites, insect stings, blisters, psoriasis, burns, sunburn, rashes, athlete's foot, eczema and dermatitis (including contact dermatitis and atopic dermatitis).

According to yet another embodiment of the invention, the crushed mollusk shell particles are dissolved in an aqueous solution. Preferably, the microparticles are incorporated into the solution at about 5% to 20% by weight. The aqueous solution may be any solution capable of dissolving the above amount of crushed mollusk shell particles as long as it is safe for topical application. Preferably, the aqueous solution is water or an active solution. In one embodiment of the invention, it is contemplated that this solution containing dissolved ground mollusk shell microparticles can be used to treat at least one skin disease. Preferably, the at least one skin disease is selected from the group consisting of hyperhidrosis and depressed keratolysis.

  According to yet another embodiment of the invention, the active solution is treated with sodium hydroxide (NaOH). Preferably, NaOH is introduced into the active solution at about 0.1% to 4% by weight. Preferably, the calcium concentration of the active solution is about 30 mg / L to 1000 mg / L or less. The addition of NaOH results in an increase in the pH of the solution when sufficiently dispersed in the solution, resulting in some precipitation of calcium. This active solution containing precipitated calcium can be used interchangeably with any of the active solutions described above in accordance with the composition of the present invention.

  As shown in FIG. 1, the extraction column (10) was composed of a 6 inch diameter, 4 foot long PVC tube with two couplings (16) closing both ends. The upper coupling (16) had a 90 ° elbow threaded with a 3/4 inch plastic tube connected to it. The upper coupling (16) and the plastic tube connected thereto represent the outlet (13) according to the invention.

  The constructed lower coupling (16) had a straight adapter screwed into the coupling stopper and was connected to a plastic tube representing the inlet (11) according to the invention. A 12 V, 360 gallon / hour pump was connected to the inlet of the column (10) and used to pass distilled water through the column (10). The top and bottom of the column (10) had the lower coupling (16) had a 3/4 nipple with a 3/4 plastic tube connected to a plastic valve and a 12V pump. Except for the same design. The two screens (14) shown in FIG. 1 were used to hold a crushed scallop shell in the passage (12a).

  The comminuted shell composition consisted of a mixture of 0.5 and 1 mm diameter scallop shell particles. The mass of the smaller particles was about 10 kg and the column (10) was filled to within 2 inches from the top coupling screen (14). The remaining part of the column (10) was filled with larger particles of 3 and 4 mm diameter.

  After the first pass of distilled water, the active solution had a high suspended solids concentration. The suspended solids concentration was found to decrease with exposure time. Table 1 shows the suspended solids concentration in the solution as measured with a Hach Company DR-2400 spectrometer. This method for measuring suspended solids is a simple and direct measurement that does not require filtration or ignition / metering steps as required by gravimetric procedures. The US Environmental Protection Agency has designated a gravimetric method for measuring solids, but this method is often used to confirm processes in factories. The test result is measured at 810 nm. This method is recorded in Hach Water Analysis Handbook, Method 8006, page 963.

The accuracy of spectroscopic methods for measuring suspended solids concentration is measured by Hach Water Analysis.
Comparison with the gravimetric method described in Handbook, Method 8271, page 947. The mass of the aluminum pan was measured to the nearest 1 mg with a Scientech 120 analytical balance. A 100 mL sample was taken in situ from the solution and placed on an aluminum pan. The dish with the sample was placed in a preheated oven and allowed to evaporate at 103-105 ° C. for about 6 hours. The dish was then removed from the oven and allowed to cool at room temperature in a desiccator.
The dish with the sample was then removed from the desiccator and weighed to the nearest 0.1 mg with a Scientificech 120 analytical balance. This was the first mass measurement of the sample. This dish and the sample were again placed in an oven preheated for 1 hour, and mass measurement was performed until the difference in results did not exceed 0.4 mg. The second measurement of mass was performed as described above. Table 2 below shows the suspended solids concentration in the solution as measured by gravimetric analysis.

In the formula:
A = sample + tray weight (mg)
B = Weight of dish (mg)

In the formula:
Dh = highest number of data results obtained D1 = lowest number of data results obtained

  As described above in Example 1, two extraction columns (10) were constructed (see FIG. 4). Two columns (10) were placed in series with the outlet of the first column (10) connected directly to the inlet of the second column (10). A 12 V, 360 gallon / hour pump was connected to the inlet of the first column (10) and was used to pass distilled water through the first and second columns (10).

The packing member of the first column (10) was made from a mixture of scallop shell particles of smaller diameter 0.5 and 1 mm. The mass of the smaller particles was about 10 kg, but the column had to be filled 2 inches below the screen (14) of the upper coupling (16). The remaining part of the column (10) was filled with the larger 3 and 4 mm diameter particles as described in Example 1.

The packing member of the second column (10) was made from crushed scallop shell particles coated with iron oxide or hematite (Fe ₂ O ₃ ). Coating the ground shell particles with iron oxide can be done by any method known to those skilled in the art. In the present invention, scallop shell coating is performed by immersing the shell in iron oxide or hematite for 4 hours and then baking the shell and solution at 200 ° C. for 4 hours. The shell must then be washed with distilled water and dried in an oven at 200 ° C. for 3 hours.

  Contaminated water with a high content of aluminum and arsenic was passed through a device comprising two extraction columns arranged in series. It was actually found that the aluminum and arsenic content of the resulting active solution was reduced to 0 mg / L.

  As shown in FIG. 1, the extraction column (10) was composed of a transparent acrylic tube having a diameter of 5.08 cm and a length of 79 cm having two couplings (16) closing both ends. The upper coupling (16) had a 90 ° elbow threaded with a 3/4 inch plastic tube connected to it. The upper coupling (16) and the plastic tube connected thereto represent the outlet (13) according to the invention.

  The constructed lower coupling (16) had a straight adapter screwed into the coupling (16) stopper and was connected to a plastic tube representing the inlet (11) according to the present invention. A 12 V, 360 gallon / hour pump was connected to the inlet of the column (10) and used to pass distilled water or reverse osmosis product water through the column (10). The top and bottom of the column (10) had the lower coupling (16) had a 3/4 nipple with a 3/4 plastic tube connected to a plastic valve and a 12V pump. Except for the same design. The two screens (14) shown in FIG. 1 were used to hold a crushed scallop shell in the passage (12a).

  Scallop shells were washed and cleaned with distilled water and then dried so that the shell temperature reached 100 ° C. The shells were then crushed and sorted by size before using a composition consisting of a mixture of scallop shell particles 3 and 4 mm in diameter. The volume and type of solvent packed in the column (10) was 1 L of water.

  In order to optimize the operating conditions, two different conditions were tested for the amount of crushed shell. The amount of shell used was A) about 0.35 lb giving a ratio of about 1 to 0.35 (w / w) water to scallop shell, or B) about 1 to 1 (w / w) water pair It was either about 1 lb giving a proportion of scallop shells. The column was filled to within 2 inches from the screen (14) of the upper coupling (16). Water was then continuously passed through the column. Under both conditions, the solvent outflow was about 2.16 L / min.

  Analysis of the resulting active solution showed some variation in the measured parameters depending on which scallop shell to water ratio was used. As can be seen from FIG. 7, the pH of the solution is very close.

Referring now to FIG. 8, the conductivity measured with micro-Siemens is shown for both of the above conditions. The latter condition (B), in which the proportion of the shell used was larger, resulted in higher conductivity. The maximum conductivity achieved over the time frame observed for both conditions was (A) 58.9 μs / cm and (B) 95.8 μs / cm.

  In order to understand the relationship between the two different conditions and the conductivity, the calcium concentration was measured. As can be seen from FIG. 9, the latter condition (B) had a considerably higher calcium concentration than the former condition (A). After the solution of condition (A) has finally passed through the column, this solution contains 20.83 times more calcium than the original solution, while the solution from condition B finally passes through the column (10). After passing, this solution contained 32.5 times more calcium than the original solution.

  Referring now to FIG. 10, turbidity measured in NTU units is presented for both of the above conditions. The measured turbidity generally decreases over time, but is very small, if any, when compared between solutions made with different proportions of shell particles to solvent. . Both conditions were able to achieve values below 1 NTU unit.

  This series of examples shows that the extraction of calcium from the ground shell particles continues to become more efficient as the ratio of ground shell particles to solvent increases. Note that milled shell particle to solvent ratios other than those described herein are all contemplated within the scope of the present specification and are based on the desired properties of the resulting active solution.

  The embodiments of the invention described herein are exemplary, and numerous modifications, variations and rearrangements can be readily envisioned to achieve substantially equal results, all of which are It is intended to be encompassed within the spirit and scope of the invention.

INDUSTRIAL APPLICABILITY The present invention provides a topically applied composition for the treatment of various skin diseases, where it is repeated through a filter / extraction column containing crushed mollusk shell particles. An active solution is prepared by filtering the liquid and then mixed with a pharmaceutically acceptable carrier. The resulting composition has a number of properties. In particular, the composition can be effectively implemented as a treatment for uncontrollable skin-related diseases. Furthermore, the present invention provides applications for mollusk shells, industrial waste generated in large quantities from fishing grounds around the world, and it is financially and environmentally appropriate to carry out this use of waste that is beneficial to the public. It is thought that.

Claims (49)

  A topically applied composition comprising an active solution mixed with a pharmaceutically acceptable carrier, wherein the solution is produced by repeatedly filtering the liquid through a filter / extraction column containing crushed mollusk shell particles A composition.   The composition of claim 1, wherein the liquid is water.   The composition according to claim 2, wherein the water is distilled water or reverse osmosis purified water.   The crushed mollusk shell is boiled at a temperature of about 100 ° C. or higher for about 15 minutes and placed in a filter / extraction column before being crushed into particles. The composition according to item.   The crushed mollusk shell is calcined at a temperature of about 300 ° C. or higher for about 15 minutes and placed in a filter / extraction column before being crushed into particles. The composition according to item.   6. The composition of any one of claims 1-5, wherein the crushed mollusk shell particles are boiled for about 15 minutes at a temperature of about 100 <0> C or higher prior to placement in the filter / extraction column. object.   The composition of any one of claims 1-6, wherein the crushed mollusk shell particles are calcined at a temperature of about 300 ° C or higher for about 15 minutes prior to placement in the filter / extraction column. object.   The composition according to any one of claims 1 to 7, wherein the concentration of calcium in the active solution exceeds 14 mg / L.   The composition according to claim 1, wherein the concentration of calcium in the active solution exceeds 20 mg / L.   The composition according to any one of claims 1 to 9, wherein the pH of the active solution is 6 to 10.   The composition according to any one of claims 1 to 10, wherein the pH of the active solution is 6.5 to 9.0.   The composition according to any one of claims 1 to 11, wherein the pH of the active solution is 7.0 to 8.0.   The composition according to any one of claims 1 to 10, wherein the turbidity of the active solution is less than 6 NTU.   The composition according to claim 1, further comprising crushed mollusk shell fine particles.   The composition according to claim 14, wherein the crushed mollusk shell particles have a particle size of 250 μM or less.   The composition according to claim 15, wherein the particle size is 150 μM or less.   17. A composition according to any one of claims 14 to 16, wherein the crushed mollusk shell microparticles are boiled for about 15 minutes at a temperature of about 100 <0> C or higher prior to addition to the composition.   18. A composition according to any one of claims 14 to 17, wherein the crushed mollusk shell microparticles are fired for about 15 minutes at a temperature of about 300 <0> C or higher prior to addition to the composition.   19. A composition according to any one of the preceding claims wherein the active solution is treated with about 0.1% to 4% sodium hydroxide of the solution prior to mixing with the carrier.   20. A composition according to any one of claims 1 to 19, wherein the carrier is a cream.   20. A composition according to any one of claims 1 to 19, wherein the carrier is a lotion.   20. A composition according to any one of claims 1 to 19, wherein the carrier is an ointment.   20. A composition according to any one of claims 1 to 19, wherein the carrier is a paste.   20. A composition according to any one of claims 1 to 19, wherein the carrier is a gel.   20. A composition according to any one of claims 1 to 19, wherein the carrier is petrolatum.   The composition according to any one of claims 1 to 19, wherein the carrier is a base emulsifying ointment.   27. The composition of claim 26, wherein the active solution is mixed with the base emulsifying ointment in a ratio of about 0.5: 1 to about 7: 1 by weight.   28. The composition of claim 27, wherein the ratio is from about 5: 1 to about 6: 1.   20. A composition according to any one of claims 1 to 19, wherein the carrier is Euserin (TM).   30. The composition of claim 29, wherein the active solution is mixed with euthelin in a ratio of about 1: 1 to about 7: 1 by weight.   32. The composition of claim 30, wherein the ratio is from about 6: 1 to about 7: 1.   A topically applied composition comprising milled mollusc shell microparticles mixed with a pharmaceutically acceptable carrier.   33. The composition of claim 32, wherein the crushed mollusk shell microparticles have a particle size of 250 [mu] M or less.   34. The composition of claim 33, wherein the particle size is 150 [mu] M or less.   35. The method of any one of claims 32-34, wherein the crushed mollusk shell microparticles are boiled for about 15 minutes at a temperature of about 100 ° C or higher before being mixed with a pharmaceutically acceptable carrier. The composition as described. 36. The method of any one of claims 32-35, wherein the crushed mollusk shell microparticles are calcined at a temperature of about 300 ° C or higher for about 15 minutes before being mixed with a pharmaceutically acceptable carrier. The composition as described.   37. A composition according to any one of claims 32-36, wherein the pharmaceutically acceptable carrier is selected from the group consisting of creams, lotions, pastes, gels, euthelin, petrolatum and base emulsified ointments.   38. The composition of any one of claims 32-37, wherein the crushed mollusk shell microparticles are mixed with a carrier at about 0.01 wt% to about 0.5 wt%.   39. The composition of any one of claims 32-38, wherein the crushed mollusk shell microparticles are mixed with a carrier at about 0.03%.   40. Use of a composition according to any one of claims 1 to 39 for the treatment of at least one skin disease.   The group consisting of psoriasis, acne, shingles, dermatoses associated with varicella-zoster virus, insect bites, insect stings, burns, sunburn, blisters, rash, psoriasis, athlete's foot and dermatitis 41. Use of the composition according to claim 40, selected from:   A composition for topical application comprising dissolving ground mollusc shellfish particles in a solution.   43. The composition of claim 42, wherein the solution is water.   44. The composition of claim 42 or 43, wherein the crushed mollusk shell particles have a particle size of 250 [mu] M or less.   45. The composition of claim 44, wherein the particle size is 150 [mu] M or less.   46. The composition of any one of claims 42 to 45, wherein the crushed mollusk shell microparticles are boiled for about 15 minutes at a temperature of about 100 <0> C or higher before being dissolved in the solution.   47. The composition of any one of claims 42 to 46, wherein the crushed mollusk shell microparticles are fired for about 15 minutes at a temperature of about 300 <0> C or higher before being dissolved in the solution.   48. Use of a composition according to any one of claims 42 to 47 for the treatment of at least one skin disease.   49. Use of the composition according to claim 48, wherein the at least one skin disease is selected from the group consisting of hyperhidrosis and depressed keratolysis.